Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice - MOOTS, R. J; HARAOUI, B; SINGH, A; MATUCCI-CERINIC, M; VAN RIEL, P. L. C. M; KEKOW, J; SCHAEVERBEKE, T; DAVIS, A; TEDESCHI, M. A; FREUNDLICH, B; CHANG, D. J (Clinical and experimental rheumatology, 2011)
Keywords: Adalimumab; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal, Humanized; Antirheumatic Agents - administration & dosage; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - physiopathology; Biological and medical sciences; Bones, joints and connective tissue. Antiinflammatory agents; Diseases of the osteoarticular system; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Dosage Calculations; Etanercept; Female; Health Status; Humans; Immunoglobulin G - administration & dosage; Immunomodulators; Inflammatory joint diseases; Infliximab; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Receptors, Tumor Necrosis Factor - administration & dosage; Severity of Illness Index; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Steroid; Immunopathology; Diseases of the osteoarticular system; Antipsoriatic agent; Rheumatology; Anti-TNF; Autoimmune disease; Inflammatory joint disease; Anti-Tumor Necrosis Factor-alpha; Immunomodulator; dose escalation; Chronic; Etanercept; Infliximab; Rheumatoid arthritis; Antirheumatic agent; Immunosuppressive agent; Adalimumab; Dose; TNF-α inhibitor